Logo image of 1MRNA.MI

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

Europe - BIT:1MRNA - US60770K1079 - Common Stock

23.9 EUR
+0.55 (+2.38%)
Last: 10/6/2025, 7:00:00 PM
Fundamental Rating

3

Overall 1MRNA gets a fundamental rating of 3 out of 10. We evaluated 1MRNA against 73 industry peers in the Biotechnology industry. While 1MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. 1MRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year 1MRNA has reported negative net income.
In the past year 1MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
In multiple years 1MRNA reported negative operating cash flow during the last 5 years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

1MRNA has a Return On Assets (-24.17%) which is in line with its industry peers.
1MRNA has a Return On Equity of -30.89%. This is in the better half of the industry: 1MRNA outperforms 64.38% of its industry peers.
Industry RankSector Rank
ROA -24.17%
ROE -30.89%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

The Gross Margin of 1MRNA (68.32%) is better than 64.38% of its industry peers.
In the last couple of years the Gross Margin of 1MRNA has declined.
1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1MRNA has been increased compared to 1 year ago.
Compared to 5 years ago, 1MRNA has more shares outstanding
Compared to 1 year ago, 1MRNA has an improved debt to assets ratio.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

1MRNA has an Altman-Z score of 3.36. This indicates that 1MRNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 1MRNA (3.36) is better than 76.71% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that 1MRNA is not too dependend on debt financing.
1MRNA has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. 1MRNA outperforms 87.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.36
ROIC/WACCN/A
WACC9.54%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 3.93 indicates that 1MRNA has no problem at all paying its short term obligations.
1MRNA's Current ratio of 3.93 is fine compared to the rest of the industry. 1MRNA outperforms 71.23% of its industry peers.
1MRNA has a Quick Ratio of 3.77. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
1MRNA has a Quick ratio of 3.77. This is in the better half of the industry: 1MRNA outperforms 71.23% of its industry peers.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.77
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

5

3. Growth

3.1 Past

1MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.04%, which is quite impressive.
Looking at the last year, 1MRNA shows a very negative growth in Revenue. The Revenue has decreased by -39.05% in the last year.
Measured over the past years, 1MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.
EPS 1Y (TTM)51.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.04%
Revenue 1Y (TTM)-39.05%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-41.08%

3.2 Future

The Earnings Per Share is expected to grow by 18.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 18.42% on average over the next years. This is quite good.
EPS Next Y-7.53%
EPS Next 2Y6.31%
EPS Next 3Y12.25%
EPS Next 5Y18.29%
Revenue Next Year-40.24%
Revenue Next 2Y-18.76%
Revenue Next 3Y-6.42%
Revenue Next 5Y18.42%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

1MRNA's earnings are expected to grow with 12.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.31%
EPS Next 3Y12.25%

More info and screens

0

5. Dividend

5.1 Amount

1MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

BIT:1MRNA (10/6/2025, 7:00:00 PM)

23.9

+0.55 (+2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners74.95%
Inst Owner ChangeN/A
Ins Owners2.55%
Ins Owner ChangeN/A
Market Cap9.30B
Analysts55.33
Price Target39.79 (66.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.41%
Min EPS beat(2)21.22%
Max EPS beat(2)29.6%
EPS beat(4)3
Avg EPS beat(4)36.52%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)-7.95%
EPS beat(12)8
Avg EPS beat(12)0.84%
EPS beat(16)11
Avg EPS beat(16)4.98%
Revenue beat(2)1
Avg Revenue beat(2)11.48%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)17.36%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)46.04%
Revenue beat(8)7
Avg Revenue beat(8)31.8%
Revenue beat(12)9
Avg Revenue beat(12)25.64%
Revenue beat(16)12
Avg Revenue beat(16)20.85%
PT rev (1m)-2.49%
PT rev (3m)-5.31%
EPS NQ rev (1m)1.24%
EPS NQ rev (3m)-13.33%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-22.52%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-8.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.54
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-6.42
EYN/A
EPS(NY)-6.88
Fwd EYN/A
FCF(TTM)-7.67
FCFYN/A
OCF(TTM)-5.91
OCFYN/A
SpS6.74
BVpS20.59
TBVpS20.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.17%
ROE -30.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.32%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 386.06%
Cap/Sales 26.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.77
Altman-Z 3.36
F-Score4
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.04%
EPS Next Y-7.53%
EPS Next 2Y6.31%
EPS Next 3Y12.25%
EPS Next 5Y18.29%
Revenue 1Y (TTM)-39.05%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-41.08%
Revenue Next Year-40.24%
Revenue Next 2Y-18.76%
Revenue Next 3Y-6.42%
Revenue Next 5Y18.42%
EBIT growth 1Y35.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.33%
EBIT Next 3Y14.92%
EBIT Next 5Y18.54%
FCF growth 1Y-364.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1093.36%
OCF growth 3YN/A
OCF growth 5YN/A